Strange particle production in 158 and 40 AA GeV/cc Pb-Pb and p-Be collisions

Results on strange particle production in Pb-Pb collisions at 158 and 40 $A$ GeV/$c$ beam momentum from the NA57 experiment at CERN SPS are presented. Particle yields and ratios are compared with those measured at RHIC. Strangeness enhancements with respect to p-Be reactions at the same beam momenta have been also measured: results about their dependence on centrality and collision energy are reported and discussed.Comment: Contribution to the proceedings of the "Hot Quarks 2004" Conference, July 18-24 2004, New Mexico, USA, submitted to Journal of Physics G 7 pages, 5 figure

Results on cascade production in lead-lead interactions from the NA57 experiment

The NA57 experiment has been designed to study the production of strange and multi-strange particles in Pb-Pb and p-Be collisions at the CERN SPS. The predecessor experiment WA97 has measured an enhanced abundance of strange particles in Pb-Pb collisions relative to p-A reactions at 160 GeV/c per nucleon beam momentum. NA57 has extended the WA97 measurements to investigate the evolution of the strangeness enhancement pattern as a function of the beam energy and over a wider centrality range. In this paper, we report results on cascade production for about the 60% most central collisions at 160 GeV/c per nucleon

Breast Cancer Stem-Like Cells Are Inhibited by a Non-Toxic Aryl Hydrocarbon Receptor Agonist

Cancer stem cells (CSCs) have increased resistance to cancer chemotherapy. They can be enriched as drug-surviving CSCs (D-CSCs) by growth with chemotherapeutic drugs, and/or by sorting of cells expressing CSC markers such as aldehyde dehydrogenase-1 (ALDH). CSCs form colonies in agar, mammospheres in low-adherence cultures, and tumors following xenotransplantation in Scid mice. We hypothesized that tranilast, a non-toxic orally active drug with anti-cancer activities, would inhibit breast CSCs.We examined breast cancer cell lines or D-CSCs generated by growth of these cells with mitoxantrone. Tranilast inhibited colony formation, mammosphere formation and stem cell marker expression. Mitoxantrone-selected cells were enriched for CSCs expressing stem cell markers ALDH, c-kit, Oct-4, and ABCG2, and efficient at forming mammospheres. Tranilast markedly inhibited mammosphere formation by D-CSCs and dissociated formed mammospheres, at pharmacologically relevant concentrations. It was effective against D-CSCs of both HER-2+ and triple-negative cell lines. Tranilast was also effective in vivo, since it prevented lung metastasis in mice injected i.v. with triple-negative (MDA-MB-231) mitoxantrone-selected cells. The molecular targets of tranilast in cancer have been unknown, but here we demonstrate it is an aryl hydrocarbon receptor (AHR) agonist and this plays a key role. AHR is a transcription factor activated by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), polycyclic aromatic hydrocarbons and other ligands. Tranilast induced translocation of the AHR to the nucleus and stimulated CYP1A1 expression (a marker of AHR activation). It inhibited binding of the AHR to CDK4, which has been linked to cell-cycle arrest. D-CSCs expressed higher levels of the AHR than other cells. Knockdown of the AHR with siRNA, or blockade with an AHR antagonist, entirely abrogated the anti-proliferative and anti-mammosphere activity of tranilast. Thus, the anti-cancer effects of tranilast are AHR dependent.We show that tranilast is an AHR agonist with inhibitory effects on breast CSCs. It is effective against CSCs of triple-negative breast cancer cells selected for anti-cancer drug resistance. These results suggest it might find applications in the treatment of breast cancer

PS1 Alzheimer's disease family with spastic paraplegia: The search for a gene modifier

PS1 mutations are associated with classic Alzheimer's disease (AD); however, some families develop AD and spastic paraplegia (SP) with brain pathology characterized by Aβ cotton wool plaques. The authors report a variant AD family with the E280Q PS1 mutation. The fact that the same PS1 mutation can be found in patients with either variant or classic AD argues in favor of the presence of a genetic modifier. The authors have excluded that this modifier effect originates from coding sequence variations in three SP genes or from a second mutation in the other AD genes.link_to_subscribed_fulltex

PS1 Alzheimer's disease family with spastic paraplegia: the search for a gene modifier

PS1 mutations are associated with classic Alzheimer's disease (AD); however, some families develop AD and spastic paraplegia (SP) with brain pathology characterized by Abeta cotton wool plaques. The authors report a variant AD family with the E280Q PS1 mutation. The fact that the same PS1 mutation can be found in patients with either variant or classic AD argues in favor of the presence of a genetic modifier. The authors have excluded that this modifier effect originates from coding sequence variations in three SP genes or from a second mutation in the other AD genes

Strange baryon production in Pb-Pb interactions at CERN SPS

Recent results on strange baryon and antibaryon production in Pb-Pb collisions at 160 GeV per nucleon from the NA57 experiment are reported. Strangeness enhancements and the transverse mass spectra properties are described

Hyperon yields in Pb - Pb collisions from NA57 experiment

ABSTRACT We report results from the experiment NA57 at CERN SPS on hyperon yields at midrapidity in Pb-Pb collisions at 158 A GeV/c and 40 A GeV/c. A, Z and R yields are compared with preliminary results from the STAR. experiment at BNL

Hyperon production in 158 and 40 A GeV/c Pb - Pb and p - Be collisions from the NA57 experiment

The NA57 experiment, at the CERN SPS has measured strange baryon and antibaryon production in Pb-Pb collisions with 158 and 40 A GeV/c beam momenta. Recent results on Lambda, Xi and Omega hyperon enhancements and from the transverse mass spectra analysis for the 158 A GeV/c data sample are presented. The energy dependence of hyperon production at mid-rapidity is discussed

MULTIPLICITY OF CHARGED PARTICLES IN PB - PB COLLISIONS AT SPS ENERGIES

The multiplicity of charged particles in the central rapidity region has been measured by the NA57 experiment in Pb-Pb collisions at the CERN SPS at two beam momenta: 158 A GeV/c and 40 A GeV/c. The value of dN(ch)/d eta at the maximum has been determined and its behaviour as a function of centrality has been studied in the centrality range covered by NA57 (about 50% of the inelastic cross section). The multiplicity increase is compatible with a logarithmic dependence on the centre of mass energy. The results are compared with those from other experiments and with the VENUS and RQMD models